中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Child-Pugh评分和ALBI分级预测经肝动脉化疗栓塞治疗不可切除肝细胞癌预后的价值比较

王哲轩 王恩鑫 夏冬东 白苇 王秋和 袁洁 李晓梅 牛静 郭文刚 李凯 殷占新 韩国宏

潘岩, 刘鲁明, 陈震, 孟志强, 林钧华, 陈颢, 沈晔华. 中西医结合治疗190例老年胰腺癌的预后分析[J]. 临床肝胆病杂志, 2014, 30(4): 330-334. DOI: 10.3969/j.issn.1001-5256.2014.04.011.
引用本文: 潘岩, 刘鲁明, 陈震, 孟志强, 林钧华, 陈颢, 沈晔华. 中西医结合治疗190例老年胰腺癌的预后分析[J]. 临床肝胆病杂志, 2014, 30(4): 330-334. DOI: 10.3969/j.issn.1001-5256.2014.04.011.
Pan Yan, Liu LuMing, Chen Zhen, Meng ZhiQiang, Lin JunHua, Chen Hao, Shen YeHua. Prognostic analysis of 190 elderly patients with pancreatic cancer treated by integrated traditional Chinese and Western medicine therapy[J]. J Clin Hepatol, 2014, 30(4): 330-334. DOI: 10.3969/j.issn.1001-5256.2014.04.011.
Citation: Pan Yan, Liu LuMing, Chen Zhen, Meng ZhiQiang, Lin JunHua, Chen Hao, Shen YeHua. Prognostic analysis of 190 elderly patients with pancreatic cancer treated by integrated traditional Chinese and Western medicine therapy[J]. J Clin Hepatol, 2014, 30(4): 330-334. DOI: 10.3969/j.issn.1001-5256.2014.04.011.

Child-Pugh评分和ALBI分级预测经肝动脉化疗栓塞治疗不可切除肝细胞癌预后的价值比较

DOI: 10.3969/j.issn.1001-5256.2020.01.025
详细信息
  • 中图分类号: R735.7

Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization

  • 摘要: 目的在经肝动脉化疗栓塞术(TACE)治疗的肝功能良好的肝细胞癌患者中,评估并比较Child-Pugh评分和ALBI分级对患者总生存情况的预测能力。方法回顾性收集2010年1月-2014年12月在空军军医大学西京消化病医院接受TACE治疗的不可切除185例HCC患者,收集患者的流行病学资料(年龄、性别、病因等),实验室检查资料(血常规、肝肾功能、凝血功能等),以及影像学检查资料(肿瘤大小、数目等),计算总生存时间,根据其基线状态以及实验室检查结果计算Child-Pugh评分和ALBI分级。使用Child-Pugh评分和ALBI评分进行危险分层,采用Kaplan-Meier绘制生存曲线,log-rank检验对总生存时间进行分析比较。Cox回归模型进行危险因素分析。通过依时ROC曲线分析和C指数比较2种评分预测生存情况的能力。结果根据ChildPugh评分,5分患者的中位生存时间及95%可信区间(95%CI)为25. 3(20. 1~30. 5)个月; 6分患者的中位生存时间为8. 6(7. 5~16. 9)个月,2者生存时间比较差异有统计学意义(P=0. 002);根据ALBI评分,1级的...

     

  • [1] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10126):1301-1314.
    [2] DURAND F,VALLA D. Assessment of prognosis of cirrhosis[J]. Semin Liver Dis,2008,28(1):110-122.
    [3] PUGH RN,MURRAY-LYON IM,DAWSON JL,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg,1973,60(8):646-649.
    [4] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.
    [5] KNOX JJ. Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival:The ALBI scoring model[J]. J Clin Oncol,2015,33(6):529-531.
    [6] TOYODA H,LAI PB,O’BEIRNE J,et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma:Application of the ALBI grade[J]. Br J Cancer,2016,114(7):744-750.
    [7] WANG YY,ZHONG JH,SU ZY,et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg,2016,103(6):725-734.
    [8] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and child-pugh classifications[J]. Liver Cancer,2017,6(3):204-215.
    [9] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.
    [10] PINATO DJ,SHARMA R,ALLARA E,et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J]. J Hepatol,2017,66(2):338-346.
    [11] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.
    [12] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
    [13] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.
    [14] SAPISOCHIN G,BARRY A,DOHERTY M,et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-totreat analysis[J]. J Hepatol,2017,67(1):92-99.
    [15] VASNANI R,GINSBURG M,AHMED O,et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation[J]. Hepatobiliary Surg Nutr,2016,5(3):225-233.
    [16] ZHAO Y,WANG WJ,GUAN S,et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma:A large-scale multicenter study of 222 patients[J]. Ann Oncol,2013,24(7):1786-1792.
    [17] SIEGHART W,HUCKE F,PECK-RADOSAVLJEVIC M. Transarterial chemoembolization:Modalities,indication,and patient selection[J]. J Hepatol,2015,62(5):1187-1195.
    [18] PINATO DJ,HOWELL J,RAMASWAMI R,et al. Review article:Delivering precision oncology in intermediate-stage liver cancer[J]. Aliment Pharmacol Ther,2017,45(12):1514-1523.
    [19] BOLONDI L,BURROUGHS A,DUFOUR JF,et al. Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma:Proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis,2012,32(4):348-359.
    [20] WANG Q,XIA D,BAI W,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:A multicentre observational study[J]. J Hepatol,2019,70(5):893-903.
  • 加载中
计量
  • 文章访问数:  1675
  • HTML全文浏览量:  32
  • PDF下载量:  288
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-08
  • 出版日期:  2020-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回